Tissue and plasma thioredoxin reductase expressions in patients with glioblastoma multiforme

J Neurol Surg A Cent Eur Neurosurg. 2013 Jul;74(4):234-8. doi: 10.1055/s-0032-1333422. Epub 2013 Mar 19.

Abstract

Background and study aims: Thioredoxin reductase (TrxR) is a redox protein that is considered to play a role in tumor progression. The purpose of this study was to assess the expression of TrxR in blood and tumor samples of glioblastoma multiforme (GBM) patients.

Patients: TrxR levels were evaluated in blood and GBM tissues extracted from 27 patients, in normal brain tissues of 12 autopsy cases, and in blood samples of 12 healthy subjects. The results were compared between tumor and control groups.

Results: The mean level of TrxR in GBM tissues (74.5 ± 14.9 U/g wet tissue) was remarkably higher than in normal brain tissues (14.8 ± 3.4 U/g wet tissue). The mean TrxR levels in blood were significantly higher in GBM patients (296.3 ± 43.6 U/mL) than in the controls (203.0 ± 11.3 U/mL).

Conclusions: These findings suggest that high levels of TrxR may be related to progression of GBM.

MeSH terms

  • Adult
  • Autopsy
  • Female
  • Glioblastoma / metabolism*
  • Glioblastoma / pathology
  • Humans
  • Karnofsky Performance Status
  • Male
  • Middle Aged
  • Thioredoxin-Disulfide Reductase / blood
  • Thioredoxin-Disulfide Reductase / metabolism*

Substances

  • Thioredoxin-Disulfide Reductase